Manufacturers are investing in key recombinant vaccines and improving product pipelines, driving growth in the market.

Registration is open for faculty to attend the Westwood Lecture Series on Jan. 28. Suresh Mittal, Distinguished Professor of Virology in the College of Veterinary Medicine, will present ...

Rising global focus on innovative oral vaccines underscores a transformative shift in immunization strategies, emphasizing ...

With rare exceptions like the oral polio vaccine and intranasal vaccines against influenza, the majority of immunizations are ...

The global pediatric vaccine market is set for unprecedented growth, with a valuation of US$ 54,130.1 million in 2023, ...

Coronavirus Disease 2019 (SARS-CoV-2) vaccine is under clinical development by Shionogi and currently in Phase III for Coronavirus Disease 2019 (COVID-19).

Convidecia is under clinical development by CanSino Biologics and currently in Phase III for Coronavirus Disease 2019 (COVID-19).

It is hard to overestimate the importance of antibodies in the frameworks of biotechnology and pharmaceutical industries.

Vaccines protect babies and children from potentially life-threatening diseases. Widespread childhood vaccination has reduced or eliminated deadly diseases like polio and smallpox. Vaccines currently ...

Vaccines and aborted fetal tissue are linked in some cases. That's because certain vaccines, such as a type of rabies vaccine, are made by cultivating the virus in fetal cells. The Janssen COVID-19 ...

These responses are five- to tenfold higher than the T-cell responses induced by the DNA vaccine or recombinant MVA vaccine alone, and produce partial protection manifest as delayed parasitemia ...

The companies are testing a recombinant protein-based coronavirus ... These are an adenovirus vector-based vaccine being developed in China by CanSino Biologics and the Beijing Institute of ...